Coexistence of Epstein–Barr Virus‐associated Lymphoproliferative Disorder and Marginal Zone B‐cell Lymphoma of the Thymus in a Patient with Rheumatoid Arthritis Treated with Methotrexate

Masakazu Fujimoto,Yoshiaki Yuba,Chenglong Huang,Yoichiro Kobashi,Itsuko Koyanagi,Hiromi Sakashita,Hironori Haga

DOI: https://doi.org/10.1111/j.1365-2559.2012.04338.x

2012-01-01

Histopathology

Abstract:that DLBCLs arising in these sites show decreased or absent expression of MHC-II, allowing tumour cells to escape from immune attack. By extrapolation, it is distinctly possible that lack of MHC-II on the EATL type II in this case allowed it to home-in on immuneprivileged sites, probably explaining the clinical presentation of vitreous involvement and imaging-confirmed brain involvement. Once in these sites, the lymphoma could expand unchecked, probably explaining the rapid neurological deterioration of the patient. Finally, very little is known of MHC-II down-regulation in T-cell lymphomas of all subtypes in general. In the light of the observations made in this case report, a lack of MHC-II on T-cell lymphomas may be relevant in the prediction of likely tumour behaviour, and alert the clinician to keep a close watch on immune-privileged sites (i.e. brain, eye, and testis) for post-treatment recurrences.